• Protease Inhibitor Cocktail: Optimizing Protein Extraction F

  2026-07-07

  Discover how the Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) serves as a protein stability enhancer for cutting-edge lipid droplet and metabolic research. This article uniquely explores mechanistic assay design and practical optimization strategies.

• Dynasore: Protocol and QC Guidance for Dynamin GTPase Inhibi

  2026-07-07

  Dynasore is a cell-permeable, reversible inhibitor for the study of dynamin-dependent endocytosis and membrane trafficking. It is best suited for researchers requiring controlled, dose-dependent inhibition of dynamin GTPases in cellular assays. Its use is not recommended for workflows that require aqueous or ethanol solubility, or for experiments where long-term compound stability in solution is critical.

• Saracatinib (AZD0530): Dual Src/Abl Kinase Inhibitor for Can

  2026-07-06

  Saracatinib (AZD0530) is a potent, selective dual Src and Abl kinase inhibitor that impedes tumor cell proliferation and migration in multiple cancer models. It functions at nanomolar concentrations and is validated across cell-based and xenograft assays. APExBIO supplies Saracatinib for research use, supporting rigorous mechanistic studies in cancer biology.

• HNRNPU K181 Lactylation Drives Serine Metabolic Rewiring in

  2026-07-06

  This study identifies HNRNPU lysine 181 lactylation as a critical regulatory mechanism that stabilizes PHGDH mRNA and drives serine metabolic reprogramming in cervical cancer. The findings uncover a new lactate-dependent axis linking post-translational modification to tumor progression, opening avenues for metabolic intervention.

• Urolithin A: Advancing Mitochondrial Biogenesis Research

  2026-07-05

  Urolithin A, a gut microbiota-derived mitophagy activator, is redefining experimental paradigms in mitochondrial quality control and anti-fibrotic research. This article delivers actionable workflows, troubleshooting guidance, and translational perspectives for scientists leveraging Urolithin A in aging, muscle, and liver fibrosis models.

• GW 6471: Advanced Dissection of PPARα Antagonism in Environm

  2026-07-04

  Explore how GW 6471, a selective PPARα antagonist, enables advanced modeling of cellular metabolism and environmental toxicology. This article uniquely bridges mechanistic insights with practical protocol guidance, revealing deeper assay implications for lipid homeostasis and disease research.

• Refining In Vitro Drug Response Assessment in Cancer Researc

  2026-07-03

  Schwartz's doctoral dissertation introduces a rigorous framework for distinguishing between cancer cell proliferation arrest and cell death in drug response studies. By advancing in vitro methodologies and clarifying key measurement distinctions, the work enhances the translational accuracy of preclinical anti-cancer drug evaluation.

• LDH Cytotoxicity Assay Kit: Practical Parameters & Best Prac

  2026-07-03

  The LDH Cytotoxicity Assay Kit provides a reliable, non-radioactive method for quantifying cell damage by measuring LDH released into the medium after membrane compromise or apoptosis. It is ideal for cell cytotoxicity measurement in cancer and neurodegenerative disease models, but is not recommended where rapid, reversible membrane perturbations or non-lytic metabolic stress are the primary endpoints.

• Atrial Natriuretic Peptide (ANP) in Cardiovascular Research

  2026-07-02

  Atrial Natriuretic Peptide (ANP) is a rat-derived peptide hormone used to investigate blood pressure homeostasis and natriuresis in cardiovascular research. This dossier outlines its precise mechanism of action, validated purity, and experimental benchmarks, supporting its adoption in studies of fluid balance and adipose tissue regulation.

• OTC–Ornithine Axis Drives Astrocyte Glycolysis Disruption in

  2026-07-02

  This study uncovers how realgar-derived arsenic disrupts the liver–brain metabolic axis, leading to central nervous system toxicity via OTC inhibition and ornithine accumulation. By revealing OTC-mediated regulation of ZBTB7A and astrocyte glycolysis, the work provides mechanistic insight into energy deficits and neurotoxicity, with implications for both toxicology and liver–brain metabolic research.

• Hexamethonium Bromide in Neuronal-Type Nicotinic AChR Resear

  2026-07-01

  Hexamethonium Bromide, as a selective antagonist of neuronal-type nicotinic AChR, enables precise dissection of autonomic ganglia function and sex-specific mechanisms in hypertension models. This article details evidence-based protocols, advanced applications, and troubleshooting strategies for leveraging this compound in neuronal signaling pathway research.

• DDX23 Restricts SVA via Caspase-Dependent Apoptotic Pathways

  2026-07-01

  This study uncovers how the host RNA helicase DDX23 suppresses Senecavirus A (SVA) replication by targeting viral proteins through distinct caspase-dependent apoptotic mechanisms. The precise mapping of viral amino acid residues and caspase interactions advances our understanding of host-pathogen dynamics and suggests new avenues for targeted antiviral development.

• XAV-939: Strategic Tankyrase Inhibition in Translational Res

  2026-06-30

  This thought-leadership article explores the mechanistic depth and translational potential of XAV-939—a next-generation tankyrase inhibitor. We dissect its role as a Wnt/β-catenin pathway modulator in cancer, fibrosis, and bone research, highlight evidence-based protocol guidance, and provide strategic insight for researchers aiming to leverage XAV-939 in preclinical and translational workflows.

• HNRNPU K181 Lactylation Drives Serine Metabolism in Cervical

  2026-06-30

  This study identifies lysine 181 lactylation of HNRNPU as a critical regulator of metabolic rewiring in cervical cancer, linking lactate-driven post-translational modification to enhanced PHGDH expression and tumor growth. The findings provide mechanistic insight into serine biosynthesis regulation and highlight a novel therapeutic axis targeting metabolic vulnerabilities in malignancy.

• Morning Training Accelerates Endurance Adaptation in Mice

  2026-06-29

  A recent study demonstrates that endurance training performed during the early active (morning) phase in mice leads to more rapid and efficient performance adaptations than identical training in the late active (afternoon) phase. These findings highlight the biological significance of exercise timing in shaping endurance capacity and underlying metabolic adaptations, informing both circadian and sports physiology research.

449 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page